Life sciences news
-
OXURION NV - First patient dosed in Part B of Phase 2 KALAHARI study evaluating multiple administrations of THR-149 versus aflibercept for treatment of Diabetic Macular Edema (DME)
Monday November 15th 2021
Read more
-
Oxurion NV announces first patient dosed in its Phase 2 Study evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)
Wednesday October 13th 2021
Read more
-
Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer
Wednesday October 6th 2021
Read more
-
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
Monday October 4th 2021
Read more
-
Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)
Monday October 4th 2021
Read more
-
OXURION announces positive results from Part A of Phase 2 Study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)
Thursday September 30th 2021
Read more
-
Mithra announces topline results for COVID-19 Phase II Study
Friday September 24th 2021
Read more
-
Donesta® Phase III: recruitment completion of American study and additional recruitment in the European study
Wednesday September 22nd 2021
Read more
-
Become a flanders.bio member
Your news here?
-
Precirix and IFE sign clinical trial manufacturing agreement
Monday September 13th 2021
Read more
-
ExeVir announces first patient enrolled in phase 1b/2 clinical study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19
Wednesday September 1st 2021
Read more
-
Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004
Monday August 30th 2021
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
